Difference between revisions of "Meningioma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
m (→NCCN) |
||
| Line 17: | Line 17: | ||
==[https://www.nccn.org/ NCCN]== | ==[https://www.nccn.org/ NCCN]== | ||
| − | *''NCCN does not have guidelines at this granular level; please | + | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf NCCN Guidelines - Central Nervous System Cancers].'' |
=Unresectable, all lines of therapy= | =Unresectable, all lines of therapy= | ||
Revision as of 16:35, 4 September 2023
| Section editor | |
|---|---|
 |
Seema Nagpal, MD Stanford University Palo Alto, CA, USA |
0 regimens on this page
0 variants on this page
|
Guidelines
EANO
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Central Nervous System Cancers.
Unresectable, all lines of therapy
Placebo
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Ji et al. 2015 (SWOG S9005) | 1992-1998 | Phase 3 (C) | Mifepristone | Did not meet primary endpoint of FFS |
No active antineoplastic treatment.
References
- SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701